Drug intelligence / Profile preview

XVR-021

Development stage: Preclinical
Lead developer: ExeVir Bio
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

XVR-021 is a neutralizing single-domain antibody (also known as a nanobody) developed by ExeVir Bio for the treatment and prevention of dengue. As a virus internalization inhibitor, it targets the dengue virus to block its entry into host cells. Single-domain antibodies (VHHs) are derived from camelid antibodies and are smaller than conventional monoclonal antibodies, allowing them to access hidden viral epitopes that traditional antibodies cannot reach. This property may enable deeper tissue penetration and more cost-effective manufacturing compared to standard monoclonal antibody therapies. The drug is currently in preclinical development for infectious diseases, specifically dengue[1][2].

Targets

E (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on XVR-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XVR-021.

Explore the full profile